GLP1R and obesity due to melanocortin 4 receptor deficiency: The safety profile of tirzepatide in this trial was consistent with findings from previous trials of tirzepatide when evaluated for the treatment of obesity27,37 or type 2 diabetes38, as well as with the safety profile of the GLP-1 receptor agonist class in patients with obesity or overweight39,40.